Topas Therapeutics GmbH

Topas Therapeutics is a clinical-stage biotechnology company based in Hamburg, Germany.

Founded in 2016, the company focuses on developing innovative therapies that promote immune tolerance for autoimmune and immune-mediated diseases. Their proprietary platform, Topas Particle Conjugates, utilizes biocompatible polymer nanoparticles to deliver disease-specific antigenic peptides, targeting liver sinusoidal endothelial cells to induce T cell tolerance. The company has achieved clinical proof of concept with its lead candidate, TPM502, which is currently preparing for a Phase 2b clinical trial in celiac disease patients. Other programs in development include TPM203 for pemphigus vulgaris and additional candidates targeting multiple sclerosis and type 1 diabetes. Topas Therapeutics aims to provide meaningful therapeutic benefits to patients with unmet medical needs through its advanced clinical pipeline.